Arcutis Biotherapeutics

ARQT

Market cap $2.06B

Overview Fund Activity

17.14 USD

+0.17

1%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

17.14

0.00

0%

1 day

1%

5 days

-2.11%

1 month

2.39%

3 months

29.26%

6 months

4.38%

Year to date

17.72%

1 year

65.28%

5 years

-37.03%

10 years

-21.38%

About: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Employees: 342

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

216% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $3.24M

37% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 65

1.21% more ownership

Funds ownership: 105.38% [Q1] → 106.59% (+1.21%) [Q2]

5% less funds holding

Funds holding: 239 [Q1] → 227 (-12) [Q2]

9% less capital invested

Capital invested by funds: $1.95B [Q1] → $1.78B (-$174M) [Q2]

17% less funds holding in top 10

Funds holding in top 10: 6 [Q1] → 5 (-1) [Q2]

22% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 45

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

5% upside

Avg. target

$20

17% upside

High target

$22

28% upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Needham Serge Belanger	$22	Buy Maintained	7 Aug 2025
Goldman Sachs Richard Law	$18	Neutral Initiated	25 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about ARQT published over the past 30 days

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms of seborrheic dermatitis in individuals with diverse skin types New data show improved quality of life and decreased impact on families for investigational ZORYVE cream 0.05% in children aged 2–5 years with atopic dermatitis Data demonstrate both ZORYVE cream 0.3% and ZORYVE foam 0.3% improved signs and symptoms of plaque psoriasis in individuals with facial and/or genital involvement WESTLAKE VILLAGE, Calif. and PARIS, Sept.

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough Award” ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined—eczema, plaque psoriasis, and seborrheic dermatitis Cream and leave-in foam options are uniquely formulated to be used anywhere on the body once per day and on diverse skin and hair types ZORYVE was shown to be safe and well-tolerated and to provide rapid and reliable symptom relief and has been chosen by healthcare providers over 1 million times WESTLAKE VILLAGE, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE was presented with a 2025 Best of Beauty Breakthrough Award by Allure magazine, which is globally recognized as the most distinguished beauty award by industry professionals and consumers.

Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 35,500 restricted stock units of Arcutis' common stock to four newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Todd Watanabe - President, CEO & Director Latha Vairavan - Chief Financial Officer Conference Call Participants Jason Jun Presentation Jason Jun Great. Well, thanks, everyone, for joining the fireside session today with the Arcutis team.

Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to topical steroids and vitamin-D analogs ZORYVE cream is uniquely formulated to be effective, safe, and well tolerated for all areas of the body, including sensitive areas such as intertriginous skin, where plaque psoriasis often presents in children WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2.

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

Zacks Investment Research

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?

Zacks Investment Research

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Foghorn Therapeutics Inc. (FHTX) have performed compared to their sector so far this year.

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

3 Biotech Catalysts Present Major Opportunity

For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability and a slump that can lead to the firm's eventual demise.

3 Biotech Catalysts Present Major Opportunity

Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate

Upgrading ARQT to buy due to explosive revenue growth, improving margins, and strong ZORYVE market adoption across multiple indications. ZORYVE now commands ~41% of non-steroidal topical psoriasis prescriptions, benefiting from dermatologist preference for steroid-sparing options and favorable insurance coverage. Key risks include fierce competition, potential generic entry, and single-asset dependency, but IP protections remain robust for now.

Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate

See News Rankings

Charts implemented using Lightweight Charts™